

Special Issue

Phage Therapy: A Biological Approach to Treatment of Bacterial Infections

Message from the Guest Editor

The emergence of antibiotic-resistant bacteria due to prolonged use, underuse, or misuse of antibiotics presents a global challenge in terms of increased morbidity, mortality, and healthcare costs. One promising alternative to treat infections caused by antibiotic-resistant bacteria is phage therapy, where the natural predators of bacteria (bacteriophages, phages) are used to kill the pathogens. Phage therapy has a 100-year history, but it was forgotten in the Western countries after the invention of antibiotics. Now renewed interest in phage therapy is emerging and new practices for this biological treatment of bacterial infections are being developed. This Special Issue "Phage Therapy: A biological Approach to Treatment of Bacterial Infections" covers different aspects of phage therapy. The issue welcomes various submission types, including original research papers, short communications, reviews, case reports, and perspectives.

Keywords: Phage therapy, Human infections, Animal infections, Pharmacokinetics, Biofilm control

Guest Editor

Dr. Saija Johanna Kiljunen

Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Haartmaninkatu 3, P.O. Box 21, 00014 Helsinki, Finland

Deadline for manuscript submissions

closed (31 March 2020)



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/30552

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)